Brief: Island Pharmaceuticals Says Got Clearance From U.S. FDA For Its ISLA-101 Investigational NDA
16/05/2023 02:16
May 16 (Reuters) - Island Pharmaceuticals Ltd ILA.AX :
* GOT CLEARANCE FROM U.S. FDA FOR ITS ISLA-101
INVESTIGATIONAL NEW
DRUG APPLICATION
* PREVIOUSLY ANNOUNCED CLINICAL HOLD FOR ISLA-101
INVESTIGATIONAL
NDA HAS BEEN LIFTED, ENABLING CLINICAL PROGRESS TO PROCEED
Source text for Eikon: ID:nASXbtCqdp
Further company coverage: ILA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic